New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 20, 2013
09:03 EDTONCYOncolytics Biotech 8M share Spot Secondary priced at $4.00
Piper Jaffray and Wedbush acted as joint book running managers for the offering.
News For ONCY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 18, 2015
06:41 EDTONCYOncolytics Biotech completes enrollment of randomized Phase II study of REOLYSIN
Subscribe for More Information
06:37 EDTONCYOncolytics Biotech completes enrollment in Phase II colorectal cancer study
Subscribe for More Information
February 17, 2015
06:40 EDTONCYOncolytics Biotech receives ODD from FDA for REOLYSIN
Subscribe for More Information
06:36 EDTONCYOncolytics Biotech granted Orphan Drug Designation for REOLYSIN by FDA
Oncolytics Biotech announced that the FDA has granted Orphan Drug Designation for its lead product candidate, REOLYSIN, for the treatment of pancreatic cancer. REOLYSIN is Oncolytics' proprietary isolate of the reovirus. Its primary mode of activity is to infect and selectively target tumours with activating Ras pathway mutations and/or over-expressions of Ras pathway elements including, amongst others, EGFR, BRAF and KRAS.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use